The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1865, Issue 2, 2016, Pages 168-175

  Mendes, Fernando ^a,b,c   Domingues, Cátia ^a   Rodrigues Santos, Paulo ^a,d,e   Abrantes, Ana Margarida ^a   Gonçalves, Ana Cristina ^a   Estrela, Jéssica ^b   Encarnação, João ^a   Pires, Ana Salomé ^a,c   Laranjo, Mafalda ^a,c   Alves, Vera ^a   Teixo, Ricardo ^a   Sarmento, Ana Bela ^a,d   Botelho, Maria Filomena ^a   Rosa, Manuel Santos ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b POLYTECHNIC INSTITUTE OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Acquire; Cancer; Immune system; Innate; Natural Killer cells; Regulator T cells

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; MEMBRANE PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 3; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNE SYSTEM EXHAUSTION; IMMUNOSURVEILLANCE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION RESPONSE; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ESCAPE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NEOPLASMS; PHYSIOLOGY;

HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE;

EID: 84958206655     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2016.02.002     Document Type: Review

References (60)

1. Hanahan D., Weinberg R.a. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013.
2. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (New York, N.Y.) 2011, 331(6024):1565-1570. 10.1126/science.1203486.
3. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 2009, 15(2):425-430. 10.1158/1078-0432.CCR-08-0149.
4. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899. 10.1016/j.cell.2010.01.025.
5. Grivennikov S.I., Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 2011, 70(Suppl. 1):i104-i108. 10.1136/ard.2010.140145.
6. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015, 65(1):5-29. 10.3322/caac.21254.
7. Kim R., Emi M., Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology 2007, 121:1-14. 10.1111/j.1365-2567.2007.02587.x.
8. Denkert C., Loibl S., Noske A., Roller M., Müller B.M., Komor M., von Minckwitz G. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010, 28(1):105-113. 10.1200/JCO.2009.23.7370.
9. Baxevanis C., Perez S. Cancer dormancy: a regulatory role for endogenous immunity in establishing and maintaining the tumor dormant state. Vaccine 2015, 3(3):597-619. 10.3390/vaccines3030597.
10. Formenti S.C., Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009, 10(7):718-726. 10.1016/S1470-2045(09)70082-8.
11. Pauken K.E., Wherry E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015, 36(4):265-276. 10.1016/j.it.2015.02.008.
12. Verdeil G., Fuertes Marraco S.A., Murray T., Speiser D.E. From T cell "exhaustion" to anti-cancer immunity. Biochim. Biophys. Acta 2015, 10.1016/j.bbcan.2015.06.007.
13. Cancer Immunology 2015, Springer Berlin Heidelberg, Berlin, Heidelberg. 10.1007/978-3-662-44006-3. N. Rezaei (Ed.).
14. Li N., Grivennikov S.I., Karin M. The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 2011, 19(4):429-431. 10.1016/j.ccr.2011.03.018.
15. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29:235-271. 10.1146/annurev-immunol-031210-101324.
16. Balkwill F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009, 9(5):361-371. 10.1038/nrc2628.
17. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9(11):798-809. 10.1038/nrc2734.
18. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357(9255):539-545. 10.1016/S0140-6736(00)04046-0.
19. Egeblad M., Nakasone E.S., Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 2010, 18(6):884-901. 10.1016/j.devcel.2010.05.012.
20. Ladoire S., Mignot G., Dabakuyo S., Arnould L., Apetoh L., Rébé C., Ghiringhelli F. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J. Pathol. 2011, 224(3):389-400. 10.1002/path.2866.
21. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Pagès F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (New York, N.Y.) 2006, 313(5795):1960-1964. 10.1126/science.1129139.
22. Pages F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., Galon J. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 2009, 27(35):5944-5951. 10.1200/JCO.2008.19.6147.
23. Camus M., Tosolini M., Mlecnik B., Pages F., Kirilovsky A., Berger A., Galon J. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009, 69(6):2685-2693. 10.1158/0008-5472.CAN-08-2654.
24. Bindea G., Mlecnik B., Fridman W.-H., Pagès F., Galon J. Natural immunity to cancer in humans. Curr. Opin. Immunol. 2010, 22(2):215-222. 10.1016/j.coi.2010.02.006.
25. Shiao S.L., Coussens L.M. The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplasia 2010, 15(4):411-421. 10.1007/s10911-010-9194-9.
26. Pittet M.J. Behavior of immune players in the tumor microenvironment. Curr. Opin. Oncol. 2009, 21(1):53-59. 10.1097/CCO.0b013e32831bc38a.
27. Dong H.P., Elstrand M.B., Holth A., Silins I., Berner A., Trope C.G., Risberg B. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am. J. Clin. Pathol. 2006, 125(3):451-458.
28. Wong S.-C., Puaux A.-L., Chittezhath M., Shalova I., Kajiji T.S., Wang X., Biswas S.K. Macrophage polarization to a unique phenotype driven by B cells. Eur. J. Immunol. 2010, 40(8):2296-2307. 10.1002/eji.200940288.
29. Crowe N.Y., Coquet J.M., Berzins S.P., Kyparissoudis K., Keating R., Pellicci D.G., Smyth M.J. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 2005, 202(9):1279-1288. 10.1084/jem.20050953.
30. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol. Res. 2009, 46(1-3):79-93. 10.1007/s12026-009-8124-7.
31. Mougiakakos D., Johansson C.C., Trocme E., All-Ericsson C., Economou M.A., Larsson O., Kiessling R. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer 2010, 116(9):2224-2233. 10.1002/cncr.24999.
32. Liston A., Gray D.H.D. Homeostatic control of regulatory T cell diversity. Nat. Rev. Immunol. 2014, 14(3):154-165. 10.1038/nri3605.
33. Peranzoni E., Zilio S., Marigo I., Dolcetti L., Zanovello P., Mandruzzato S., Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 2010, 22(2):238-244. 10.1016/j.coi.2010.01.021.
34. Teng M.W.L., Swann J.B., von Scheidt B., Sharkey J., Zerafa N., McLaughlin N., Smyth M.J. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res. 2010, 70(7):2665-2674. 10.1158/0008-5472.CAN-09-1574.
35. Soukup K., Wang X. Radiation meets immunotherapy - a perfect match in the era of combination therapy?. Int. J. Radiat. Biol. 2015, 91(4):299-305. 10.3109/09553002.2014.995383.
36. Pedroza-Gonzalez A., Xu K., Wu T.-C., Aspord C., Tindle S., Marches F., Palucka A.K. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J. Exp. Med. 2011, 208(3):479-490. 10.1084/jem.20102131.
37. Zenz T. Exhausting T cells in CLL. Blood 2013, 121(9):1485-1486. 10.1182/blood-2013-01-475939.
38. Balkhi M.Y., Ma Q., Ahmad S., Junghans R.P. T cell exhaustion and interleukin 2 downregulation. Cytokine 2015, 71(2):339-347. 10.1016/j.cyto.2014.11.024.
39. Mapara M.Y., Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2004, 22(6):1136-1151. 10.1200/JCO.2004.10.041.
40. Cuddapah S., Barski A., Zhao K. Epigenomics of T cell activation, differentiation, and memory. Curr. Opin. Immunol. 2010, 22(3):341-347. 10.1016/j.coi.2010.02.007.
41. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., Rosenberg S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-and are functionally impaired. Blood 2009, 114(8):1537-1544. 10.1182/blood-2008-12-195792.
42. Qin Y., Wang G., Yang J., Liu C. Generation of a monoclonal antibody recognizing mouse PD-1. Monoclonal Antibodies Immunodiagnosis Immunother. 2014, 33(5):361-364. 10.1089/mab.2014.0024.
43. Sakuishi K., Ngiow S.F., Sullivan J.M., Teng M.W.L., Kuchroo V.K., Smyth M.J., Anderson A.C. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2013, 2(4). 10.4161/onci.23849.
44. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-and PD-pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207(10):2187-2194. 10.1084/jem.20100643.
45. Kong Y., Zhang J., Claxton D.F., Ehmann W.C., Rybka W.B., Zhu L., Zheng H. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015, 5. 10.1038/bcj.2015.58.
46. Jeremic B. Advances in radiation oncology in lung cancer. Radiation Oncology 2005, 121. Springer, Berlin/Heidelberg. Second Edi., 10.1007/b137825. J. Branislav (Ed.).
47. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., Katoh H. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br. J. Cancer 2006, 94(January):275-280. 10.1038/sj.bjc.6602934.
48. Hald S.M., Bremnes R.M., Al-Shibli K., Al-Saad S., Andersen S., Stenvold H., Donnem T. CD4/CD8 co-expression shows independent prognostic impact in resected non-small cell lung cancer patients treated with adjuvant radiotherapy. Lung Cancer (Amsterdam, Netherlands) 2013, 80(2):209-215. 10.1016/j.lungcan.2012.12.026.
49. Derer A., Deloch L., Rubner Y., Fietkau R., Frey B., Gaipl U.S. Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses - pre-clinical evidence and ongoing clinical applications. Front. Immunol. 2015, 6:505. 10.3389/fimmu.2015.00505.
50. Perez C.A., Fu A., Onishko H., Hallahan D.E., Geng L. Radiation Induces an Antitumour Immune Response to Mouse Melanoma 2010.
51. Kepp O., Galluzzi L., Lipinski M., Yuan J., Kroemer G. Cell death assays for drug discovery. Nat. Rev. Drug Discov. 2011, 10(3):221-237. 10.1038/nrd3373.
52. Zitvogel L., Kepp O., Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010, 140(6):798-804. 10.1016/j.cell.2010.02.015.
53. Green D.R., Ferguson T., Zitvogel L., Kroemer G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 2009, 9(5):353-363. 10.1038/nri2545.
54. Panaretakis T., Joza N., Modjtahedi N., Tesniere A., Vitale I., Durchschlag M., Kroemer G. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008, 15(9):1499-1509. 10.1038/cdd.2008.67.
55. Multhoff G., Botzler C., Jennen L., Schmidt J., Ellwart J., Issels R. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J. Immunol. 1997, 158(9):4341-4350. (Baltimore, Md.: 1950).
56. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.-P., Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120(2):457-471. 10.1172/JCI40483.
57. Murshid A., Gong J., Calderwood S.K. Heat shock protein 90 mediates efficient antigen cross presentation through the scavenger receptor expressed by endothelial cells-I. J. Immunol. 2010, 185(5):2903-2917. 10.4049/jimmunol.0903635.
58. Elsner L., Flügge P.F., Lozano J., Muppala V., Eiz-Vesper B., Demiroglu S.Y., Dressel R. The endogenous danger signals HSP70 and MICA cooperate in the activation of cytotoxic effector functions of NK cells. J. Cell. Mol. Med. 2010, 14(4):992-1002. 10.1111/j.1582-4934.2008.00677.x.
59. Ma Y., Aymeric L., Locher C., Kroemer G., Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr. Opin. Immunol. 2011, 23(1):146-152. 10.1016/j.coi.2010.09.008.
60. Durante M., Reppingen N., Held K.D. Immunologically augmented cancer treatment using modern radiotherapy. 19 Trends in Molecular Medicine 2013, 565-582. Elsevier Ltd. 10.1016/j.molmed.2013.05.007.